From Biomarkers,to Breakthroughs.
Our platform addresses the bottleneck in solid tumor cell therapies by predicting and selecting immune cells with superior infiltrating potential.
Optimizing efficacy across the entire development pipeline.
Donor Selection
Identify better starting materials
Lead Discovery
Identify promising lead candidates
Product Characterization
Identify the most potent cells
Cell Manufacturing
Optimize bioprocessing workflows
Translational Biomarkers
Identify biomarkers for improved outcomes
Our applications.
Discover how infiltration biomarkers drive data-driven decisions at every stage of cell therapy development.
Donor Selection
Identify adhesion profiles that predict infiltration potential.
Your cell therapy's success starts with choosing the right starting materials. Our adhesion biomarker screening identifies donor populations with superior infiltration potential. By selecting cells with the strongest baseline adhesion profiles, you characterize cellular potential before cell engineering begins.
Predictive tumor infiltration and superior therapeutic outcomes in preclinical model
In preclinical studies published in Cell Reports, CD8+ T cells enriched using our platform demonstrated significant improvements in both tumor homing and therapeutic efficacy.
- 3-4x improved tumor homing: Adherent cells showed statistically significant superior tumor infiltration compared to free-flowing cells (P=0.0343)
- Enhanced tumor control: Adhesion-enriched cells combined with checkpoint blockade achieved superior tumor growth inhibition (two-way ANOVA, p<0.05)
- Predictive biomarker: In vitro adhesion behavior directly correlated to in vivo therapeutic performance
Camargo CP, Muhuri AK, Alapan Y, et al. Adhesion analysis via a tumor vasculature-like microfluidic device identifies CD8+ T cells with enhanced tumor homing to improve cell therapy. Cell Reports (2023)
Ready to identify which cells will infiltrate tumors and deliver results?
Our proprietary adhesion characterization platform reveals the biomarkers that predict cell therapy performance, accelerating your development timeline.
Request a ConsultationOur scientific collaborators and partners
Built on world-class partnerships
